Risk reward profile is outstanding here.Apart from the consistent insider buying it is now entering a phase where they will start marketing their own line of mushroom supplements. In addition they will begin supplying a natural psilocybin product all around the world. Whats interesting is they went back to the Health Canada and recieved approval to double the amount of product they can produce based on a defineable demand to supply trials throughout North America and Europe. At .22 the risk imo is negligible and the upside is promising. When the man who built Lulu Lemon is an advisor and his son one of the founders you have to take this Company seriously. GLTA